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Abstract
Introduction and hypothesis Long-term safety concerns have risen over the mid-urethral sling operation (MUS) for stress urinary
incontinence (SUI), which in some countries has led to litigations and even suspending MUS insertions. We examined the long-
term re-procedure rate after MUS operations. Themain outcomewas re-procedures for SUI. The secondary outcome was surgical
interventions due to complications.
Methods We analysed a retrospective population cohort of 3531 women with MUS operations in 2000–2006 and followed them
up until 31 December 2016. Data were collected from a national hospital register and from hospital patient records.
Results The median follow-up time was 13 years (IQR 11.6–14.8) for the 3280 women with a retropubic MUS (RP-MUS) and
11 years (IQR 10.3–11.9) for the 245 women with a transobturator MUS (TO-MUS). The cumulative number of re-procedures
for SUI was 16 (0.5%) at 1 year, 66 (1.9%) at 5 years, 97 (2.8%) at 10 years and 112 (3.2%) at 17 years. This risk was higher after
TO-MUS than after RP-MUS operations (OR 3.6, 95% CI 2.5–5.2, p < 0.001). The cumulative number of any long-term re-
procedure was 43 (1.2%) at year 1, 105 (3.0%) at year 5, 144 (4.1%) at year 10 and 163 (4.6%) at year 17.
Conclusions Re-procedures occur up to 17 years after primary MUS insertion, but their incidence is low after the first few
postoperative years. Re-procedures for recurrent SUI are more common after TO-MUS than RP-MUS.
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Introduction
Urinary incontinence affects up to 40% of women [1], and 10–
14% of women are estimated to go through an operation for
stress urinary incontinence (SUI) during their lifetime [2, 3].
Studies have proven the mid-urethral sling operation (MUS)
to be an effective and safe treatment for SUI in the short- and
medium term [4], and it has become the current gold standard
treatment for SUI.
However, using surgical mesh in pelvic floor operations has
raised concerns about long-term problems such as chronic pain,
mesh exposure, dyspareunia, voiding dysfunctions and the need
for re-operations to treat complications or recurrent SUI. The US
Food and Drug Administration, the Scottish government and the
National Health Service (NHS England) concluded in their re-
views that complications following these operations are not rare
and thatmorecomprehensiveevidenceon long-termrisksofmesh
operations isneeded [5–7]. Inpreviouscohort studieswith follow-
up times of up to 10 years, 4.3–4.5%ofwomen received a further
surgical treatment for SUI [8, 9], and, including mesh-removal
procedures, 4.6–6.9% ofwomen had a re-operation [9, 10].
With our register-based population study, we assess the
long-term re-procedure rate after MUS with a follow-up time
up to 17 years. The main focus was on re-procedures for SUI,
but we also evaluated complications and surgical interven-
tions to treat them. We combined register data with hospital
records to determine the complication types and their treat-
ment in detail.
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The sample included all retropubic (RP-MUS) and
transobturator (TO-MUS) MUS operations performed in the
Hospital District of Helsinki and Uusimaa (HUS) from
January 1, 2000, to December 31, 2006. This hospital district
comprises two university hospitals and five regional hospitals
with a population of 1.6 million people as of 2017. Re-
operations were included from the index operation until the
end of 2016, which resulted in a follow-up time of 10 to
17 years (median 13.2, IQR 11.3–14.7).
We identified the sample women from the HUS hospital
records and from the national Care Register for Health Care
(Care Register). This register is composed of regulated notifi-
cations that every public Finnish health care-providing institute
is obligated by law to submit for every in- and hospital out-
patient visit. These notifications include admission and dis-
charge dates and all diagnosis and procedure codes.
Therefore, the Care Register includes all re-procedures per-
formed in the public sector in Finland. Of all MUS procedures
in Finland, 98.4% were performed in the public sector during
our study period (National Institute for Health andWelfare).We
identified the sample by searching all visits with Nordic
Medico-Statistical Committee Classification of Surgical
Procedures (NCSP) operation codes for the MUS operation
(LEG10, LEG12 and LEG13). The preoperative incontinence
typewas considered as SUI if the ICD-10 diagnosis code for the
operation was N39.3, mixed urinary incontinence (MUI) if it
was N39.4 and unknown if any other diagnosis code was used.
We identified 3509 women from the hospital records and
3334 from the Care Register.Combined, 3299 (93.1%) of 84
3544 women were found from both sources, 210 (5.9%) only
85 from the hospital records and 35 (1.0%) only from the Care
86 Register; 6 women found only in the Care Register were
excluded because of male sex or age < 18 years (Fig. 1). We
validated the data on a sample of 1010 women (392 women
selected randomly and all the 618 women with a potential
complication, see below). We compared their register data
and hospital records, which were available for 990 (98.0%)
of the selected women. All these women had visits related to
urinary incontinence, but we identified four women with a
planned MUS operation that was not performed and three
women who had undergone a sling operation not included in
this study (mini-sling TVT Secur). These seven women were
excluded from further analysis. We also identified six cases
where the sling was not placed because of an intraoperative
bladder perforation. These women were included in the im-
mediate complication analysis but not in the long-term com-
plication analysis. All the remaining 977 women whose pa-
tient records were evaluated had a MUS insertion in the index
period. After validation, a sample of 3531 women remained
for immediate complication analysis and 3525 women for
long-term complication analysis. We were able to identify all
women who had died during the follow-up time (n = 435,
12.3%), but we could not get information on migration to
other countries as well as on operations or treatments in an-
other country than Finland.
Complications and re-procedures were identified from the
Care Register. The index MUS operation and all subsequent
visits were identified, and diagnosis and operation codes were
used to define complications (see detailed list of the codes
used in Appendix Table 5). Subsequent visits with diagnosis
or operation codes clearly indicating that the visit was unre-
lated to urological or gynecological issues were excluded. To
gather more detailed information on the nature and treatment
of the complication, we read and evaluated hospital records of
the 618 (17.5%) women with a potential MUS complication
or re-operation based on the Care Register. For 594 (96.1%) of
these women, the patient records were available for the hos-
pital visit and we were able to confirm if they were related to a
MUS complication included in this study.
The main outcome, re-procedure for SUI, was defined as a
recurrent SUI operation (MUS, urethral bulking injection,
colposuspension or bladder neck needle suspension; the two
latter were not present among the cohort) ≥ 90 days after the
index operation. Only the first re-procedure for SUI was re-
ported for each woman.
Secondary outcomes were complications and re-
procedures due to complications. In immediate complications,
we included perioperative organ perforations (only bladder
and urethra perforation among the cohort), any surgical inter-
ventions to treat a complication ≤ 30 days postoperatively and
surgical intervention to treat sling exposure 90 days postoper-
atively. In later complications, we included all sling-related re-
procedures that were not already reported in the immediate
complications. Exposure was defined as a condition of
displaying, revealing or exhibiting mesh or making the mesh
accessible [11], and exposures after recurrent MUS operations
were also included. The surgical treatment of MUS exposure
was divided into sling reburial (covering the exposed sling
without resecting the sling), partial sling resection (exposed
sling excised without intercepting the sling) and sling resec-
tion (exposed sling excised intercepting the sling). Sling cut
was defined as an incision of the sling into two pieces in the
absence of sling exposure and sling mobilizing as loosening
the sling without resecting it. Tissue exploration or laparosco-
py to remove sling material as completely as possible was
referred to as sling removal.
The National Institute for Health and Welfare of Finland
authorized the use of the Care Register data (THL/958/
5.05.00/2017), andHUS authorized the use of hospital records
(HUS/138/2017). The register authorities assessed the ethics
of the study and, as no contact with the subjects was included,
the study was exempted from evaluation by an Ethics
Committee. In advance, we performed a preliminary estima-
tion of the sample size.
728 Int Urogynecol J (2020) 31:727–735
IBM SPSS Statistics 25 was used for statistical analysis. To
compare groups, we used the Student’s t-test for continuous var-
iables and the chi-squared or Fisher’s exact test, when appropri-
able, for categorical variables. To calculate confidence intervals,
we used Clopper-Pearson for binomial variables and Student’s t-
test for continuous variables. We used Kaplan-Meier to estimate
survival and Cox regression to analyse hazard ratios (HR). We
used odds ratio (OR) to assess the association between re-
operations and index MUS type, Kaplan-Meier to estimate sur-
vival and Cox regression to analyse hazard ratios (HR).
Results
The study included 3531 women: 3286 (93.1%) with RP-MUS
and 245 (6.9%) with TO-MUS operations (Table 1). The median
follow-up time was 13.2 years (IQR 11.3–14.7) for the whole
sample: 13 years (IQR 11.6–14.8) for the 3280 women with RP-
MUS and 11 years (IQR 10.3–11.9) for 245 women with TO-
MUS. The median age (58 years; IQR 50–67) did not differ
between the groups. Most of the operations were performed for
SUI in both groups, while concomitant operations were more
common in women with RP-MUS (7.7% vs. 3.7%, p = 0.02).
Immediate complications occurred in 76 (2.2%) MUS opera-
tions (Table 2). This rate did not differ (p = 0.4) between the two
groups (2.1% for RP-MUS and 2.4% for TO-MUS). Bladder
perforation was the most common complication (n= 41; 1.2%)
and it occurred only in the RP-MUS group, as did all heavy
bleedings that led to a laparotomy (n = 6, 0.2%). Immediate sling
exposures took place more often with TO-MUS (2.0% vs. 0.4%;
OR= 4.6, 95% CI 2.2–9.6 with p = 0.05). The detailed data on
immediate complications are found in Table 2.
Fig. 1 Sample cases obtained from the hospital records and Care Register. MUS mid-urethral sling, Care Register Care Register for Health Care, RP-
MUS retropubic mid-urethral sling, TO-MUS trans-obturator mid-urethral sling
Int Urogynecol J (2020) 31:727–735 729
Re-procedures for SUI were performed on 112 women
(3.2%): 52 (46.4%) new RP-MUS operations, 20 (17.9%)
new TO-MUS operations, 38 (33.9%) urethral bulking injec-
tions with Bulkamid® and 2 (1.8%) urethral bulking injec-
tions with Zuidex® (Table 3). The cumulative number of
new SUI procedures was 16 (0.5%) at 1 year, 66 (1.9%) at 5
years, 97 (2.8%) at 10 years and 112 (3.2%) at 17 years
(Fig. 2). The risk for a new SUI procedure was higher in the
TO-MUS group than in the RP-MUS group (OR 3.6, 95% CI
2.5–5.2 with p = 0.05), and the median time until re-procedure
was shorter in the TO-MUS group (1.8 years) than in the RP-
MUS group (4.6 years, p = 0.008) (Table 3). This difference
persisted even if the risk was adjusted for the year of opera-
tion, incontinence type, immediate exposure and age
(Table 4). Women with mixed urinary incontinence and im-
mediate complications had a significantly greater risk for a
new SUI procedure.
In long-term re-operations for MUS complications (n = 75;
2.1%), exposure was the most common cause: 46 cases in the
RP-MUS group (1.4%) and 5 cases in the TO-MUS group
(2.0%). The sling was cut in 25 (0.7%) RP-MUS: 14 (56%)
for voiding difficulties, 3 (12%) for pain, 3 (12%) for urge
symptoms and 5 (20%) for unknown reasons, while no TO-
MUS slings were cut in the long term (Table 3). The sling was
removed in six (0.2%) women due to either an infection or
sling exposure in the bladder or urethra.
The cumulative number of any long-term re-operation after
MUS was 43 (1.2%) at year 1, 105 (3.0%) at year 5, 144
(4.1%) at year 10 and 163 (4.6%) at year 17. At 13 years,
the end of TO-MUS follow-up time, the rate for any long-
term reoperation was 3.5% for RP-MUS operations and
11.8% for TO-MUS operations. At 17 years, the end of the
RP-MUS follow-up time, the rate for any long-term reopera-
tion was 4.1% for the RP-MUS women. The overall rate for
immediate complications or any long-term re-operation was
5.2% (n = 184) at the end of the follow-up time.
Discussion
In a cohort of 3525 women with a follow-up time up to
17 years after a MUS operation, there were few (3.2%) re-
operations due to recurrent SUI. Even though re-operations
continued to occur throughout the follow-up period, the inci-
dence was moderate after the first few postoperative years. At
the end of the follow-up, 4.6% of the women had gone
Table 1 Demographics of the 3531 women undergoing a MUS operation during 2000 to 2006
All MUS (3531) RP-MUS (3286) TO-MUS (245) p value
Age, mean in years (±SD) 58.5 (11.6) 58.5 (11.6) 58.5 (12.0) 1.0
Urinary incontinence type, number (%) < 0.001
Stress urinary incontinence 2961 (83.9) 2867 (87.2) 94 (38.4)
Mixed urinary incontinence 367 (10.4) 345 (10.5) 22 (9.0)
Undefined 203 (5.7) 74 (2.3) 129 (52.7)
Concomitant operations, number (%)
Any operation 264 (7.5) 255 (7.8) 9 (3.7) 0.02
Any pelvic organ prolapse operation 169 (4.8) 164 (5.0) 5 (2.0) 0.04
Anterior colporraphy 48 (1.4) 47 (1.4) 1 (0.4) 0.3
Posterior colporraphy 74 (2.1) 72 (2.2) 2 (0.8) 0.2
Hysterectomy 25 (0.7) 24 (0.7) 1 (0.4) 1.0
Operating hospital, number (%) < 0.01
University clinics 1898 (53.8) 1729 (52.6) 169 (69.0)
Regional clinics 1633 (46.2) 1557 (47.4) 76 (31.0)
Operation year, number (%) 0.02
2000 412 (11.7) 412 (12.5) –
2001 445 (12.6) 445 (13.5) –
2002 669 (18.9) 669 (20.4) –
2003 564 (16.0) 559 (17.0) 5 (2.0)
2004 511 (14.5) 454 (13.8) 57 (23.3)
2005 503 (14.2) 434 (13.2) 69 (28.2)
2006 427 (12.1) 313 (9.5) 114 (46.5)
Median follow-up time, years (IQR) 13.2 (11.3–14.7) 13.4 (11.6–14.8) 11.0 (10.3–11.9)
Alive at follow-up end (%) 3090 (87.7) 2869 (87.5) 221 (90.2) 0.21
MUS mid-urethral sling, RP-MUS retropubic mid-urethral sling, TO-MUS trans-obturator mid-urethral sling
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through a long-term re-operation, most of which were re-
operations for SUI.
Almost all immediate complications, except sling expo-
sure, followed only RP-MUS operations. Even though blad-
der perforation was the most common immediate complica-
tion, the occurrence was still low (1.2%) compared with the
bladder perforation rate of 4.5% reported in the Cochrane
review and the rate of 3.8% in a Finnish national cohort study
[4, 12]. However, bladder perforation does not usually require
a new operation when detected intraoperatively, and it did not
increase the re-operation risk, whereas any immediate compli-
cation and immediate sling exposure did.
Our results concur with previous long-term studies that
have reported a higher risk for SUI re-operation after TO-
MUS compared with RP-MUS [8, 13]. The steep V-shaped
angle of the tape in the RP-MUS operation may enhance the
long-term efficacy, and the latest NHS guideline recommends
using RP-MUS in standard situations [14]. However, the re-
operation rates after RP-MUS and TO-MUS differed already
in the first few postoperative years, unlike in previous short-
and mid-term studies [4], and their difference was also larger
than in previous long-term studies [8, 13]. Preceding sling cut
or removal or previous incontinence operations cannot explain
this difference in re-operation risk because they were more
common with RP-MUS. Of the 31 slings that were cut in
our study, only one occurred in the TO-MUS group; the most
common indication was voiding difficulties, which is known
to be more common after RP-MUS than TO-MUS [4]. A
learning curve is a plausible partial reason for the deviance
in the re-procedure rate; TO-MUS was first introduced in
Finland during our study period without strict operator restric-
tions, whereas performing RP-MUS independently required
an obligatory training period. However, the learning curve
cannot fully explain the difference because the higher risk
for re-operation for SUI persisted when only the year 2006
was considered (OR 3.3, 95% CI 1.8–6.1). Nevertheless, our
total rate (3.2%) for SUI re-operations was comparable to that
of the previous retrospective long-term cohort studies (1.9 to
Table 2 Immediate
complications after the MUS
operations (n, %, 95% CI) and
odds ratios (95% CI)
All MUS (n = 3531) RP-MUS (n = 3286) TO-MUS (n = 245)
Any complication 76 (2.2, 1.7–2.7) 70 (2.1, 1.7–2.7) 6 (2.4, 0.9–5.3)
Odds ratio – – 1.1 (0.5–2.5)
Any immediate re-operation 36 (1.0, 0.7–1.4) 30 (0.9, 0.6–1.3) 6 (2.4, 0.9–5.3)
Odds ratio – – 2.4 (1.2–5.1)
Perforations, n (%, 95% CI) 42 (1.2, 0.9–1.6) 42 (1.3, 0.9–1.7) –
Bladder 41 41 –
Urethra 1 1 –
No MUS due to perforation 6 6 –
Perforation detected postoperatively 4 4 –
Any sling-specific complication 26 (0.7, 0.5–1.1) 20 (0.6, 0.4–0.9) 6 (2.4, 0.9–5.3)
Exposure 16 (0.5, 0.3–0.7) 11 (0.3, 0.2–0.6) 5 (2.0, 0.7–4.7)
Odds ratio – – 4.6 (2.2–9.6)
Exposure treatment
-Sling reburied 3 1 2
-Sling partially resected 2 2 –
-Sling resected 6 4 2
-More than one surgical intervention 2 1 1
-Treatment unknown 3 3 –
Sling cut or mobilized 6 (0.2) 5 (0.2) 1 (0.4)
Voiding difficulties 2 2 –
Pain 1 1 –
Reason unknown 3 2 1
Sling removed 5 (0.1) 5 (0.2) –
Perforation detected postoperatively 4 4 –
Fistula 1 1 –
Laparotomy due to heavy bleeding 6 (0.2) 6 (0.2) –
Additional suture due to bleeding 1 (0.03) 1 (0.03) –
Draining of haematoma or abscess 3 (0.1) 3 (0.1) –
MUS mid-urethral sling, RP-MUS retropubic mid-urethral sling, TO-MUS trans-obturator mid-urethral sling
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4.5%) [8, 10, 15]. With these retrospective data, we cannot
determine how the type (RP-MUS versus TO-MUS) of the
index operation or re-procedure for SUI was selected.
In other long-term re-operations, the most common was a
sling-specific surgical intervention (2.9%). This figure is in line
with previous studies that reported a 3.3% rate for partial or total
sling removal at 9 years [8] and 2.8% rate for sling shortening,
reburying, incision or excision [15]. In our study, exposure was
the most common reason for sling resections and for all sling
revisions. Sling reburial and resection without cutting the sling
carried a risk for a new sling revision; for 15.7%with exposure, a
second procedure was needed after the initial sling reburial or
resection. However, as sling cutting and removal is associated
with up to 61% risk for SUI symptom relapse, minimal mesh
Table 3 Long-term complications after MUS operations (n, %, 95% CI) and odds ratios (95% CI)
All MUS (3525) RP-MUS (3280) TO-MUS (245)
Any re-procedure 163 (4.6, 0.4–5.4) 134 (4.1, 3.4–4.8) 29 (11.8, 8.1–16.6)
Odds ratio – – 2.8 (1.9–3.9)
Years to re-procedure, median in years (IQR) 3.0 (0.8–6.9) 3.5 (1.0–7.9) 1.6 (0.7–4.8)
Re-procedure for SUI 112 (3.2, 2.6–3.8) 86 (2.6, 2.1–3.2) 26 (10.6, 7.1–15.2)
Odds ratio – – 3.6 (2.5–5.2)
Years to re-procedure, median (IQR) 4.1 (1.7–7.7) 4.6 (3.0–8.8) 1.8 (0.9–5.5)
Re-procedure type
New RP-MUS 52 (46.4) 33 (38.4) 19 (73.1)
New TO-MUS 20 (17.9) 20 (23.3) 0
Urethral bulking injection 40 (35.7) 33 (38.4) 7 (26.9)
Sling cut, resected or removed before re-procedure for SUI 21 (18.8) 17 (19.8) 4 (15.4)
Previous incontinence operation before index MUS operation 12 (13.5) 10 (15.2) 2 (8.7)
Surgical intervention other than re-procedure for SUI 75 (2.1, 1.7–2.7) 70 (2.1, 1.7–2.7) 5 (2.0, 0.7–4.7)
Odds ratio – – 1.0 (0.4–2.3)
Years to surgical intervention, median (IQR) 1.4 (0.5–5.9) 1.6 (0.5–6.4) 0.6 (0.3–2.5)
Previous incontinence operation before index MUS operation 4 (7.5) 2 (4.1) 2 (50.0)
Any sling-specific surgical intervention 71 (2.0, 1.6–2.5) 66 (2.0, 1.6–2.6) 5 (2.0, 0.7–4.7)
Odds ratio – – 1.0 (0.4–2.4)
Years to surgical intervention, median (IQR) 1.4 (0.5–5.9) 1.6 (0.5–6.4) 0.6 (0.3–2.5)
Exposure 46 (1.3, 1.0–1.7) 41 (1.3, 0.9–1.7) 5 (2.0, 0.7–4.7)
New MUS before exposure 16 (27.1) 14 (26.4) 2 (33.3)
Exposure location
-Vagina 42 (91.3) 38 (92.7) 4 (80.0)
-Bladder 1 (2.2) 1 (2.4) 0
-Urethra 1 (2.2) 1 (2.4) 0
-Unknown 2 (4.3) 1 (2.4) 1 (20.0)
Exposure treatment
Sling re-buried 2 (4.3) 1 (2.4) 1 (20.0)
Sling partially resected 9 (19.6) 9 (22.0) 0
Sling resected 27 (58.7) 23 (56.1) 4 (80.0)
Multiple surgical interventions for exposure 8 (17.4) 8 (19.5) 0
Sling removal 6 (0.1, 0.0–0.3) 6 (0.2, 0.1–0.4) 0
Reason for sling removal
Chronic infection and fistula 3 (50.0) 3 (50.0) 0
Chronic infection without fistula 1 (16.7) 1 (16.7) 0
Exposure in bladder or urethra 2 (33.3) 2 (33.3) 0
Sling cut 25 (0.7, 0.5–0.1) 25 (0.8, 0.5–1.1) 0
Reason for sling cutting
Voiding difficulties 14 (56.0) 14 (56.0) 0
Pain 3 (12.0) 3 (12.0) 0
Urge symptoms 3 (12.0) 3 (12.0) 0
Unknown 5 (20.0) 5 (20.0) 0
Granuloma removed, n (%) 4 (0.1) 4 (0.1) 0
Abscess drained, n (%) 3 (0.1) 3 (0.1) 0
MUS mid-urethral sling, RP-MUS retropubic mid-urethral sling, TO-MUS trans-obturator mid-urethral sling, SUI stress urinary incontinence
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revisionmay be reasonable [16]. Similar to re-operations for SUI,
any other surgical intervention took place earlier and was more
common with TO-MUS women than RP-MUS women. This is
in line with the previously reported lower sling removal rate after
RP-MUS vs. TO-MUS (HR 0.72, 95% CI 0.62–0.84) [8].
The strength of our study was that we were able to check
the data validity in our sample: 99.3% of the women had a
MUS operation at the target period, and the re-operations
checked from patient records had been reported accurately.
Our sample and outcomes are clinically representative be-
cause of the unselected population that includes 25% of all
MUS operations performed in Finland in 2006 (National
Institute for Health and Welfare). A further strength of our
study is the long follow-up time of up to 17 years. Long
Table 4 Risk factors for re-
procedure for SUI Univariate analysis HR 95% CI, p = 0.05 p value
Age (continuous) 1.0 1.0 1.0 0.10
Operation type
RP-MUS 1 (ref)
TO-MUS 4.8 3.1 7.5 < 0.01
Year
2000 to 2003 1 (ref)
2004 to 2006 2.3 1.6 3.4 < 0.01
Incontinence type
Stress urinary incontinence 1 (ref)
Mixed and other urinary incontinence 1.8 1.1 3.0 0.02
Immediate complications
Any immediate complication 6.5 3.5 12.1 < 0.01
Immediate exposure 23.9 11.6 49.2 < 0.01
Perforation 1.8 0.4 7.3 0.4
TO-MUS adj. with operation year < 0.01
2004 to 2006 (ref: 2000 to 2003) 1.7 1.1 2.6 0.02
Multivariate analysis HR 95% CI, p = 0.05 p value
TO-MUS adj. with operation year, incontinence
type, immediate exposure and age
< 0.01
2004 to 2006 (ref: 2000 to 2003) 1.6 1.1 2.5 0.03
Mixed and other urinary incontinence (ref: SUI) 1.8 1.1 3.0 0.02
Immediate exposure 13.7 6.2 30.0 < 0.01
Age (continuous) 1.0 1.0 1.0 0.14
TO-MUS (ref: RP-MUS) 3.2 1.9 5.4 < 0.01
SUI stress urinary incontinence, RP-MUS retropubic mid-urethral sling, TO-MUS trans-obturator mid-urethral
sling
Fig. 2 Survival without re-
procedure for SUI (%)
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follow-up time is needed to assess the lifetime risks for re-
operation after MUS operation for recurrent SUI or MUS-
related complication, which continued to occur throughout
our follow-up time, although at a moderate rate.
The main limitation of our study was the inability to assess
the incidence of recurrent SUI, pain, dyspareunia and lower
urinary tract symptoms problems unless they were treated
surgically. However, surgical intervention is a very robust
and thus reliable end point to detect a recurrent SUI, as well
as other complications. In addition, we were not able to
completely determine some important patient characteristics,
such as previous incontinence operations, BMI, comorbidities
and smoking status. However, when we compared the patient
records of women with re-operations with a group of 139
randomly selected patients, there were no significant differ-
ences in the rate of previous incontinence operations.
In conclusion, our results suggest that RP-MUS has a better
long-term efficacy than TO-MUS in treating SUI. In our data,
RP-MUS included a higher risk for bladder perforation and re-
procedure for heavy bleeding and voiding difficulties, and
TO-MUS included a higher re-procedure risk for mesh expo-
sure. Long-term re-operations for MUS complications can
occur, but the incidence is low after the first few postoperative
years.
The use of MUS procedure is now under re-evaluation in
many countries. In our view, the results of our study show an
acceptable risk level for long-term complications. For clini-
cians who perform this operation, these results help to inform
their patients of long-term re-operation risk.
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Appendix
Table 5 Diagnosis codes (ICD-10) and operation codes (NCSP) found in the cohort and used to identify visits for MUS complication
ICD-10 NOMESCO
N30* Cystitis
N31* Neuromuscular dysfunction of bladder, not elsewhere classified
N32* Other disorders of bladder
N33* Bladder disorders in diseases classified elsewhere
N34* Urethritis and urethral syndrome
N35* Urethral stricture
N36* Other disorders of urethra
N37* Urethral disorders in diseases classified elsewhere
N39.0 Urinary tract infection, site not specified
N39.3 Stress incontinence
N39.4 Other specified urinary incontinence
N99* Intraoperative and postprocedural complications and disorders of genitourinary
system, not elsewhere classified
N99.6 Intraoperative haemorrhage and haematoma of a genitourinary system organ or
structure complicating a procedure
R30* Pain associated with micturition
R31* Haematuria
R32* Unspecified urinary incontinence
R34* Anuria and oliguria
R36* Urethral discharge
R39* Other and unspecified symptoms and signs involving the genitourinary system
R52* Pain, unspecified
T81* Complications of procedures, not elsewhere classified
T83* Complications of genitourinary prosthetic devices, implants and grafts
KWE* Reoperation for deep haemorrhage in urological
surgery
LEG96 Other vaginal operation for incontinence
LEG00 Vaginal urethrocystorrhaphy
LEG20 Plastic repair of female pelvic floor with levator
division
KDG* Operations on female urethra and bladder neck for
urinary incontinence
KDV20 Submucous urethral injection
KDV22 Transluminal endoscopic submucous urethral
injection
LWL03 Reoperation for gynaecological pelvic organ
prolapse mesh
KDH* Reconstructive operations on urethra
KDW* Other operations on urethra
KKF* Removal of foreign body from retroperitoneal space
KCF* Removal of foreign body from bladder
KKW* Other operations on retroperitoneal space
KCH* Reconstructive operations on bladder
KCW* Other operations on bladder
KWW* Other reoperation in urological surgery
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